CBRE vs STRO
CBRE Group Inc Class A (CBRE) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported CBRE revenue for 2024-12-31 was $35.77B. Net income was $1.04B. Revenue was up 12.0% from 2023-12-31 to 2024-12-31. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
CBRE currently screens at market cap $41.66B and trailing P/E 42.7. STRO currently screens at market cap $470.8M.
Not investment advice. Open the CBRE and STRO stock pages for the full models.
Not investment advice.